Phase 1: China Approves Groundbreaking Drug for Bone Metastases SKB107
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxRedefining Prostate Cancer Care: The LIBERTAS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase I Clinical Trial of AZD2284, AZD2287, and AZD2275
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 trial: Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFutureChem Launches Phase 3 Trial for Novel PSMA-Targeted Radiopharmaceutical FC705
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxEVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxIMGS-101: Phase 1/2 Clinical Trial Begins for Hypoxia-Reversing Agent in Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025